^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Title:
Correlation Analysis between T790M Status and Clinical Characteristics of Patients with EGFR-sensitive Mutation Advanced NSCLC who Progressed after the First-line EGFR-TKIs Administration: A Real-world Exploratory Study
Published date:
06/06/2023
Excerpt:
CONTRADICTING EVIDENCE: Furthermore, The median PFS of the initial EGFR-TKIs administration was longer among patients with T790M positive mutation and patients with PR reaction than those without T790M mutation and patients with stable disease (SD), respectively (median PFS: 13.6 vs 10.9 months, P=0.023) and (median PFS: 14.0 vs 10.1 months, P=0.001).
DOI:
10.2174/1386207326666230606100729
Source:
Title:
P34.01 - Utility of Assessment of the EGFR Resistance Genotype using Cell-Free DNA and CTCs from Liquid Biopsies
Published date:
01/12/2021
Excerpt:
In addition, the potential clinical utility of CTC numbers in monitoring response to therapy and the emergence of resistance (T790M) were assessed….The emergence of the T790M resistance mutation was detected in 57% of patients during treatment with EGFR TKIs. In contrast to cohort 2, patients in cohort 1 with a T790M had a worse OS and shorter TTP relative to patients with an EGFR sensitizing mutation.
Source:
Title:
P84.22 - Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina
Published date:
01/12/2021
Excerpt:
CONTRADICTING EVIDENCE: Advanced NSCLC patients harboring uncommon (other than L858R and exon 19 deletion) EGFR mutations at baseline tissue biopsy were selected...three patients harboring concurrent de-novo resistant T790M and a common sensitive EGFR mutation (L858R or exon 19del) achieved partial response using first and second-generation EGFR-TKIs.
